Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 2/3 1

Status

Active not recruiting 2Completed 1

Sponsor Class

INDUSTRY 3NETWORK 1

Study Type

Interventional 3

Sponsor

Cancer Type

Myeloid 3Other hematologic neoplasm 1

Conditions

Myelodysplastic Syndromes 3Recurrence 1Primary Myelofibrosis 1Myeloproliferative Disorders 1Leukemia, Myeloid, Acute 1

Interventions

Paclitaxel 337pembrolizumab 332Carboplatin 330Cisplatin 277Gemcitabine 264Docetaxel 251Bevacizumab 239Nivolumab 230Pemetrexed 211Rituximab 183Dexamethasone 183Cyclophosphamide 169Capecitabine 169Trastuzumab 149Fluorouracil 147Ipilimumab 121atezolizumab 118Prednisone 117Erlotinib Hydrochloride 116Oxaliplatin 109Cetuximab 104Sunitinib 101Leucovorin 97Doxorubicin 97Lenalidomide 93Irinotecan 89130-nm albumin-bound paclitaxel 84durvalumab 77Bortezomib 77Azacitidine 73

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Has results × imetelstat × Clear all
NCT05583552 2026-05-12

IMpress

GCP-Service International West GmbH

Phase 2 Active not recruiting
46 enrolled 21 charts
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT02598661 2026-01-05

Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

Geron Corporation

Phase 2/3 Active not recruiting
289 enrolled 35 charts 1 FDA
Myeloid

Myelodysplastic Syndromes, Recurrence

NCT01731951 2021-09-21

Imetelstat Sodium in Treating Participants With Primary or Secondary Myelofibrosis

Geron Corporation

Phase 2 Completed
80 enrolled 31 charts
Myeloid

Myelodysplastic Syndromes, Myeloproliferative Disorders, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡